Selank Research: What Published Studies Have Investigated
Selank research is the study of a synthetic tuftsin-analog heptapeptide. This page summarises what the literature investigated — chemistry, the tuftsin lineage, and the mechanisms examined — cited neutrally and framed as “studies investigated.” A defining honest angle: much of the primary literature is Russian-published, and the findings are largely preclinical.
What is Selank?
What is Selank? It is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro — a stabilised analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail for protease resistance. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.
Origin and development
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the V.V. Zakusov Institute of Pharmacology, in work associated with Myasoedov, Seredenin and Kozlovskaya. That Russian research lineage is the honest reason much of the primary literature is published in Russian-language journals with limited English translation. These are molecule-history facts.
Molecule properties
Selank is a heptapeptide of seven amino acids; the Pro-Gly-Pro extension makes it markedly more stable than native tuftsin, and in research catalogues it is supplied as a lyophilized powder. An N-acetyl variant (N-acetyl-Selank) also appears in some studies. Molecule facts only — no administration guidance.
Mechanisms researchers have examined
The Selank mechanism literature is pleiotropic, with no single confirmed receptor target. Each direction below is framed as what researchers examined:
- GABAergic neurotransmission — Volkova et al. (2016, Front Pharmacol) examined Selank’s effect on the expression of genes involved in GABAergic neurotransmission by RT-PCR in rats. The honest nuance: Filatova, Kolomin et al. (2017, Front Pharmacol), testing Selank in human IMR-32 neuroblastoma cells, reported no direct effect on the studied GABAergic genes in isolation — a mixed and qualified finding, not a settled mechanism.
- BDNF expression — Inozemtseva et al. (2008, Doklady Biological Sciences) reported that intranasal Selank was associated with changes in Bdnf mRNA and BDNF protein levels in rat hippocampus in a study model.
- Enkephalin system — Zolotarev et al. (late 1990s) examined Selank’s effect on enkephalin-degrading enzyme (enkephalinase) activity in vitro.
- Neuroimmune / cytokine signalling — studies examined effects on cytokine balance, including IL-6, in stimulated blood-cell cultures (PMID 18683560).
The section closes as the literature does: no single confirmed receptor target; the mechanisms remain under investigation and are described as pleiotropic. Each bullet names a pathway examined, not an effect in a reader.
Research models in the literature
Preclinical rodent behavioural models and in-vitro neuronal and blood-cell cultures dominate the literature. On the human side, described neutrally: Zozulya et al. (2008, Zh Nevrol Psikhiatr im. S.S. Korsakova; English translation in Neuroscience and Behavioral Physiology) studied Selank in patients with generalized anxiety disorder and neurasthenia, compared with a benzodiazepine (medazepam). Reported accurately, this is a study that investigated Selank and what it compared — it does not prove a benefit, and it does not mean a reader would experience any effect. The overall picture: most evidence is preclinical, human data is limited and largely Russian-published, and animal or in-vitro findings cannot establish human outcomes.
A practical consequence of that Russian-language lineage is that several of the primary reports reach an English-reading audience only as translations or as secondary summaries. That is worth stating because a translated abstract can flatten the qualifications an original paper placed on its own findings — a mechanism described as “examined” or “associated with” in the source can harden into something more definite once it has passed through a summary. For that reason the citations here point back to the named studies, and every mechanism above is reported as what was investigated rather than what was concluded about people.
Selank in the nootropic-peptide research group
In one line: Selank’s GABAergic research arm is often set against Semax’s neurotrophic research arm. Where the Semax literature clusters around neurotrophic factors such as BDNF and NGF, the Selank record is weighted toward GABAergic gene-expression and enkephalin-system work — the two are pursued as separate mechanistic questions in the literature rather than ranked against each other. Both are heptapeptides of Russian origin studied largely in preclinical settings, which is why they are so often discussed as a pair. Beyond that single contrast the detail belongs on the sibling pages: for the head-to-head, see the sibling comparison Semax vs Selank; for Semax’s own literature, see Semax research. This page deliberately hands off rather than rebuilding the comparison table.
Research-grade sourcing and verification
For laboratory research use only, Selank is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and quality framing only.
Verify a batch
Every order ships with a per-batch Certificate of Analysis. Have a vial in hand? Enter its lot number to look up the COA for that exact batch.
Frequently asked questions
What is Selank derived from?
What is Selank’s amino acid sequence?
What mechanisms have researchers studied for Selank?
Is most Selank research published in English?
Has Selank been studied in humans?
Literature cited
- Volkova A, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016.
- Filatova E, Kolomin T, et al. “GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.” Frontiers in Pharmacology. 2017;8:89.
- Inozemtseva LS, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Doklady Biological Sciences. 2008 (DOI 10.1134/S0012496608040066).
- Zozulya AA, Neznamov GG, Seredenin SB, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zh. Nevrol. Psikhiatr. im. S.S. Korsakova. 2008;108(4):38–48 (Russian; English transl. Neuroscience and Behavioral Physiology).
- Zolotarev YuA, et al. Studies on Selank and enkephalin-degrading enzyme activity in vitro. Late 1990s.
- Cytokine / IL-6 neuroimmune study — PMID 18683560.
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. All products are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use, ingestion, or administration. Nothing on this page is a medical or efficacy claim. You must be 21 or older to browse this catalog.